Skeletal 18 F-PSMA-1007 uptake in prostate cancer patients.

Autor:	Janssen J; Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Groningen 9713GZ, The Netherlands., Noordzij W; Department of Radiology and Nuclear Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Velleman T; Department of Radiology and Nuclear Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., de Jong IJ; Department of Urology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Langendijk JA; Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Verzijlbergen JF; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands., Stormezand GN; Department of Radiology and Nuclear Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Aluwini S; Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Jazyk:	angličtina
Zdroj:	Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2023 Jun 29; Vol. 15, pp. 17588359231179311. Date of Electronic Publication: 2023 Jun 29 (Print Publication: 2023).
DOI:	10.1177/17588359231179311
Abstrakt:	Background/objectives: Accurate and uniform interpretation and reporting of metastatic prostate cancer (PCa) lesions on prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) are indispensable. 18 F-PSMA-1007 is increasingly used because of its favorable imaging characteristics. However, increased non-specific skeletal uptake may be an important pitfall of this radioligand. Therefore, we aimed to assess the interobserver variation in reporting skeletal 18 F-PSMA-1007 uptake on PET/CT. Design/methods: In total, 33 18 F-PSMA-1007 PET/CT scans of 21 patients with primary PCa and 12 patients with biochemical recurrence were included, and a total of 85 skeletal lesions were evaluated by three independent observers. The primary endpoint was the interobserver variability of the likelihood of malignancy of the skeletal lesions on both patient and lesion level (kappa analysis). Results: Observers qualified most lesions as not malignant (81-91%) and the overall mean interobserver agreement was moderate on both patient (κ: 0.54) and lesion level (κ: 0.55). In 52 lesions without corresponding CT substrate, the rating resulted in not malignant in 95-100%. Availability of additional imaging (60% of lesions) did not improve interobserver agreement (κ: 0.39 on lesion level) and resulted in unchanged rating for all observers in 78%. Conclusion: This interobserver analysis of skeletal 18 F-PSMA-1007 uptake resulted in moderate agreement, in line with rates reported in literature. Importantly, the presence of non-specific skeletal uptake without CT substrate, as a potential shortcoming of 18 F-PSMA-1007, did not impair interobserver agreement. Competing Interests: The authors declare that there is no conflict of interest. (© The Author(s), 2023.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu